Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

The race for research and lab space in New Haven

The New Haven area has become a hub for thriving and growing young bioscience companies like Arvinas and Cybrexa Therapeutics, which are working to develop...

| By Kelley Gipson

InveniAI® adds new products to its AI discovery suite

InveniAI® Corporation has expanded its flagship AI- and ML-driven innovation monitoring platform, AlphaMeld™ to include products for pharmaceutical drug discovery and development stakeholders. TargetMeld™ and...

| By Kelley Gipson

Rallybio expands leadership team

Rallybio reports that it has added Amanda Hayward, PhD and Lisa Sinclair to the Rallybio team. Dr. Hayward will focus on further building Rallybio’s portfolio and Ms....

| By Kelley Gipson

IsoPlexis gets grant from National Cancer Institute

IsoPlexis has received $2 million in grant funding from the National Cancer Institute’s Small Business Innovation Research Development Center for the advancement of intracellular proteomic pathway...

| By Kelley Gipson

Advancing health at The Jackson Laboratory

Over the course of 40 days on the International Space Station (ISS), researchers will determine the effect of microgravity on JAX’s Mighty Mice — genetically...

| By Kelley Gipson

Gov. Lamont names execs to workforce council

Connecticut Gov. Ned Lamont has named two dozen business and nonprofit executives, and several state and union officials, to a newly revamped group aimed at...

| By Kelley Gipson

Arvinas reports positive data re PROTAC® platform

Arvinas has announced a platform data update that includes initial safety, tolerability, and pharmacokinetic data from the company’s ongoing Phase 1 clinical trials of ARV-110...

| By Kelley Gipson

Alexion’s ULTOMIRIS® approved against AHUS

Alexion Pharmaceuticals reports that the FDA has approved ULTOMIRIS® (ravulizumab-cwvz) for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA)...

| By Kelley Gipson

Melinta gains BAXDELA® approval from FDA

Melinta Therapeutics reports that the FDA has approved BAXDELA® (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by designated susceptible...

| By Kelley Gipson

New Vanessa Hungarian office focuses on sun safety

Vanessa Research recently opened a branch office in Győr, Hungary. Located on the campus of Széchenyi István University, the office serves as an innovation hub...